Pioneering Science for Patient Choice
Pharvaris is a late-stage biopharmaceutical company developing novel oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks. Its lead asset, deucrictibant, is in two pivotal Phase 3 trials (CHAPTER-3 for prophylaxis and RAPIDe-3 for on-demand treatment), aiming to deliver injectable-like efficacy with the convenience of oral administration.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2023
Nov 2020
Sep 2019
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Health insurance company using technology to make health care simple, affordable, and accessible.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
